Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer

Oppenheimer raised the firm’s price target connected Palvella Therapeutics (PVLA) to $200 from $120 and keeps an Outperform standing connected the shares aft the institution reported the Phase 2 TOIVA readout for Qtorin rapamycin successful cutaneous venous malformations. The steadfast says 10 of 15 patients presented arsenic “much improved” oregon “very overmuch improved” implicit conscionable 12 weeks.

Claim 50% Off TipRanks Premium and Invest with Confidence

• Unlock hedge-fund level information and almighty investing tools designed to assistance you marque smarter, sharper decisions

• Stay up of the marketplace with the latest quality and investigation truthful your portfolio is ever positioned for maximum potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See Insiders’ Hot Stocks connected TipRanks >>

Read More connected PVLA:

Disclaimer & DisclosureReport an Issue

• Palvella Therapeutics terms people raised to $212 from $122 astatine Lucid Capital

• Palvella Therapeutics Reports Positive Phase 2 Study Results

• Palvella Therapeutics announces topline results from Phase 2 TOIVA trial

• Positive Buy Rating for Palvella Therapeutics Driven by Promising Developments successful DSAP Treatment

• Palvella Therapeutics: Promising Biopharmaceutical Growth with QTORIN Platform Advancements